Dr. Vivek Ashok Rudrapatna, MD, PhD

Dr. Rudrapatna practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Rudrapatna's NPI, 1255750741, was assigned on April 10, 2014. Dr. Rudrapatna graduated from Icahn School Of Medicine At Mount Sinai in 2014. Dr. Rudrapatna holds California license A140681.

Dr. Rudrapatna's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Rudrapatna's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Rudrapatna is also affiliated with Salinas Valley Health Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Rudrapatna to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rudrapatna practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Rudrapatna's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Rudrapatna is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Rudrapatna's licenses on file in 2 states: California and Texas.

Dmand AI lists acid reflux, chronic inflammatory bowel disease (IBD), colonoscopy, intestinal or bowel obstruction, irritable bowel syndrome (IBS), peptic ulcer and upper GI endoscopy among the conditions Dr. Rudrapatna treats.

CMS data shows 63 Medicare services from Dr. Rudrapatna across 2 procedure codes in 2024, for 61 Medicare patients. Medicare paid $4,453 for them.

CMS counts 61 Medicare patients who saw Dr. Rudrapatna in 2024. The largest group is 65 to 74, with 37 patients. 67% of them have high blood pressure, and 64% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rudrapatna's median patient age at 61, with 49% women.

In 2024, Dr. Rudrapatna wrote 79 Medicare Part D claims for 25 patients. 75% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $329,594 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Rudrapatna for performance year 2024, reported as part of a group. Dr. Rudrapatna accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rudrapatna as offering telehealth. CMS counts 17 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Rudrapatna, more than 48% of the clinicians it reports for that procedure.

Dmand AI links 25 papers to Dr. Rudrapatna, published from 2013 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Inflammatory Bowel Diseases, Electronic Health Records and Colitis, Ulcerative. Dr. Rudrapatna has published most often in medRxiv. Dr. Rudrapatna's most frequent co-authors are Vivek Rudrapatna, MD, Debajyoti Datta, MD and Perseus Vistasp Patel, MD.

CMS Open Payments shows 81 general payments to Dr. Rudrapatna from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Abbvie Inc. paid the most, $2,702.

Dr. Rudrapatna graduated from Icahn School Of Medicine At Mount Sinai in 2014.

Dr. Rudrapatna is in network with 9 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.